Scant Pipeline Competition For Roche’s Novel Flu Antiviral
Executive Summary
With Priority Review given to Roche’s novel flu antiviral baloxavir marboxil for potential approval in the US, and Shionogi’s launch of the product under the brand name Xofluza, it looks set to lead the market for single-dose antivirals.
You may also be interested in...
Prophylaxis Results Set Stage For Expanded Japan Xofluza Use
Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Roche Registers Fresh Win For New Flu Drug
Ahead of an FDA decision scheduled for December 24, the Swiss major's baloxivir has improved influenza symptoms versus placebo, and to a lesser extent Roche's own Tamiflu, in people at high risk of serious complications from the virus.